Cerevel Therapeutics/CERE

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX

About Cerevel Therapeutics

Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Ticker

CERE

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Cambridge, United States

Employees

355

CERE Metrics

BasicAdvanced
$7.5B
Market cap
-
P/E ratio
-$2.74
EPS
1.47
Beta
-
Dividend rate
$7.5B
1.47
10.22
10.121
84.822
85.445
-46.34%
-29.79%
-92.45%
13.3
13.3
-18.71
8.33%
19.12%

What the Analysts think about CERE

Analyst Ratings

Majority rating from 9 analysts.
Hold

CERE Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$132M
-0.53%
Profit margin
0.00%
NaN%

CERE Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 19.39%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.63
-$0.61
-$0.76
-$0.73
-
Expected
-$0.65
-$0.63
-$0.59
-$0.61
-$0.62
Surprise
-2.86%
-3.51%
27.75%
19.39%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Cerevel Therapeutics stock?

Cerevel Therapeutics (CERE) has a market cap of $7.5B as of July 04, 2024.

What is the P/E ratio for Cerevel Therapeutics stock?

The price to earnings (P/E) ratio for Cerevel Therapeutics (CERE) stock is 0 as of July 04, 2024.

Does Cerevel Therapeutics stock pay dividends?

No, Cerevel Therapeutics (CERE) stock does not pay dividends to its shareholders as of July 04, 2024.

When is the next Cerevel Therapeutics dividend payment date?

Cerevel Therapeutics (CERE) stock does not pay dividends to its shareholders.

What is the beta indicator for Cerevel Therapeutics?

Cerevel Therapeutics (CERE) has a beta rating of 1.47. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy or sell Cerevel Therapeutics stock

Buy or sell Cerevel Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing